Compare · EVMN vs NVO
EVMN vs NVO
Side-by-side comparison of Evommune Inc. (EVMN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $173.66B, about 806.9x EVMN ($215.2M).
- EVMN has been more active in the news (4 items in the past 4 weeks vs 3 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 14 for EVMN).
- Company
- Evommune Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $215.2M
- $173.66B
- 1M return
- -
- -10.14%
- 1Y return
- -
- -30.36%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 4
- 3
- Recent ratings
- 14
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EVMN
- SEC Form 4 filed by Evommune Inc.
- UBS initiated coverage on Evommune with a new price target
- Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
- Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
- Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Atopic Dermatitis
- Needham initiated coverage on Evommune with a new price target
- Amendment: SEC Form SCHEDULE 13G/A filed by Evommune Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank